[
  {
    "ts": null,
    "headline": "Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season",
    "summary": "Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings results soon.",
    "url": "https://finnhub.io/api/news?id=5c33e62ec9ac46c3e7a93a34534126ef0117bed0a6cd4d9b53bde2d7c0defdab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769789655,
      "headline": "Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season",
      "id": 138307366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings results soon.",
      "url": "https://finnhub.io/api/news?id=5c33e62ec9ac46c3e7a93a34534126ef0117bed0a6cd4d9b53bde2d7c0defdab"
    }
  },
  {
    "ts": null,
    "headline": "Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis",
    "summary": "Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD).Regulatory submission is planned in the first half of 2026. TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOB",
    "url": "https://finnhub.io/api/news?id=d0d69cef1f465f58b447e15fb35c56deb495bb2b391907616095d609237bdb0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769778000,
      "headline": "Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis",
      "id": 138305383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD).Regulatory submission is planned in the first half of 2026. TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOB",
      "url": "https://finnhub.io/api/news?id=d0d69cef1f465f58b447e15fb35c56deb495bb2b391907616095d609237bdb0f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen gives up on its once-prized eczema drug",
    "summary": "The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.",
    "url": "https://finnhub.io/api/news?id=408b68c4174eb02c18612f15511d99b92ab6d1a83f8c3b53eeb1b20094f8fb85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769774220,
      "headline": "Amgen gives up on its once-prized eczema drug",
      "id": 138307367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.",
      "url": "https://finnhub.io/api/news?id=408b68c4174eb02c18612f15511d99b92ab6d1a83f8c3b53eeb1b20094f8fb85"
    }
  }
]